Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 163

1.

Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort.

Willis R, Seif AM, McGwin G Jr, Martinez-Martinez LA, González EB, Dang N, Papalardo E, Liu J, Vilá LM, Reveille JD, Alarcón GS, Pierangeli SS.

Lupus. 2012 Jul;21(8):830-5. doi: 10.1177/0961203312437270. Epub 2012 Feb 17.

PMID:
22343096
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Effects of statins on proinflammatory/prothrombotic biomarkers and on disease activity scores in SLE patients: data from LUMINA (LXXVI), a multi-ethnic US cohort.

Willis R, Seif AM, McGwin G Jr, Martinez-Martinez LA, González EB, Doan E, Dang N, Papalardo E, Liu J, Vilá LM, Reveille JD, Alarcón GS, Pierangeli SS.

Clin Exp Rheumatol. 2014 Mar-Apr;32(2):162-7. Epub 2014 Jan 24.

PMID:
24480124
[PubMed - indexed for MEDLINE]
3.

Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus.

Sacre K, Criswell LA, McCune JM.

Arthritis Res Ther. 2012 Jun 27;14(3):R155. doi: 10.1186/ar3895.

PMID:
22734582
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Cytokine imbalance in systemic lupus erythematosus: a study on northern Indian subjects.

Arora V, Verma J, Marwah V, Kumar A, Anand D, Das N.

Lupus. 2012 May;21(6):596-603. doi: 10.1177/0961203311434937. Epub 2012 Feb 2.

PMID:
22300832
[PubMed - indexed for MEDLINE]
5.

Increased IL-18 in patients with systemic lupus erythematosus: relations with Th-1, Th-2, pro-inflammatory cytokines and disease activity. IL-18 is a marker of disease activity but does not correlate with pro-inflammatory cytokines.

Amerio P, Frezzolini A, Abeni D, Teofoli P, Girardelli CR, De Pità O, Puddu P.

Clin Exp Rheumatol. 2002 Jul-Aug;20(4):535-8.

PMID:
12175109
[PubMed - indexed for MEDLINE]
6.

Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study.

Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, Panoskaltsis-Mortari A, Gregersen PK, Behrens TW, Baechler EC.

Arthritis Rheum. 2009 Oct;60(10):3098-107. doi: 10.1002/art.24803.

PMID:
19790071
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus.

Rose T, Grützkau A, Hirseland H, Huscher D, Dähnrich C, Dzionek A, Ozimkowski T, Schlumberger W, Enghard P, Radbruch A, Riemekasten G, Burmester GR, Hiepe F, Biesen R.

Ann Rheum Dis. 2013 Oct;72(10):1639-45. doi: 10.1136/annrheumdis-2012-201586. Epub 2012 Oct 31.

PMID:
23117242
[PubMed - indexed for MEDLINE]
8.

Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L).

Alarcón GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alén J, Bastian HM, Vilá LM, Reveille JD; LUMINA Study Group.

Ann Rheum Dis. 2007 Sep;66(9):1168-72. Epub 2007 Mar 27.

PMID:
17389655
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events.

Ho KT, Ahn CW, Alarcón GS, Baethge BA, Tan FK, Roseman J, Bastian HM, Fessler BJ, McGwin G Jr, Vilá LM, Calvo-Alén J, Reveille JD.

Rheumatology (Oxford). 2005 Oct;44(10):1303-7. Epub 2005 Jul 19.

PMID:
16030085
[PubMed - indexed for MEDLINE]
Free Article
10.

Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis.

Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, Ellingson S, Newman B, Bauer JW, Peterson EJ, Baechler EC, Reed AM.

Arthritis Rheum. 2009 Nov;60(11):3436-46. doi: 10.1002/art.24936.

PMID:
19877033
[PubMed - indexed for MEDLINE]
Free Article
11.

Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: its correlation with disease activity.

Sabry A, Sheashaa H, El-Husseini A, Mahmoud K, Eldahshan KF, George SK, Abdel-Khalek E, El-Shafey EM, Abo-Zenah H.

Cytokine. 2006 Aug;35(3-4):148-53. Epub 2006 Oct 5.

PMID:
17027280
[PubMed - indexed for MEDLINE]
12.
13.

Increased serum β2-microglobulin is associated with clinical and immunological markers of disease activity in systemic lupus erythematosus patients.

Hermansen ML, Hummelshøj L, Lundsgaard D, Hornum L, Keller P, Fleckner J, Fox B, Poulsen LK, Jacobsen S.

Lupus. 2012 Sep;21(10):1098-104. doi: 10.1177/0961203312447668. Epub 2012 May 10.

PMID:
22577117
[PubMed - indexed for MEDLINE]
14.

The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus.

Toubi E, Kessel A, Rosner I, Rozenbaum M, Paran D, Shoenfeld Y.

Scand J Immunol. 2006 Apr;63(4):299-303.

PMID:
16623930
[PubMed - indexed for MEDLINE]
15.

Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-α and TNF-α in systemic lupus erythematosus.

Ma CY, Jiao YL, Zhang J, Yang QR, Zhang ZF, Shen YJ, Chen ZJ, Zhao YR.

Rheumatol Int. 2012 Feb;32(2):395-402. doi: 10.1007/s00296-010-1636-6. Epub 2010 Dec 1.

PMID:
21120500
[PubMed - indexed for MEDLINE]
16.

Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity.

Wu Q, Yang Q, Lourenco E, Sun H, Zhang Y.

Arthritis Res Ther. 2011 Jun 16;13(3):R88. doi: 10.1186/ar3363.

PMID:
21679442
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective?

Gómez D, Correa PA, Gómez LM, Cadena J, Molina JF, Anaya JM.

Semin Arthritis Rheum. 2004 Jun;33(6):404-13.

PMID:
15190525
[PubMed - indexed for MEDLINE]
18.

Serum IL-6, TNFalpha, p55 srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus.

Davas EM, Tsirogianni A, Kappou I, Karamitsos D, Economidou I, Dantis PC.

Clin Rheumatol. 1999;18(1):17-22.

PMID:
10088943
[PubMed - indexed for MEDLINE]
19.

Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission.

Wais T, Fierz W, Stoll T, Villiger PM.

J Rheumatol. 2003 Oct;30(10):2133-9.

PMID:
14528506
[PubMed - indexed for MEDLINE]
20.

Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics.

Omdal R, Mellgren SI, Koldingsnes W, Jacobsen EA, Husby G.

J Rheumatol. 2002 Mar;29(3):482-6.

PMID:
11908560
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk